Iterum Therapeutics plc (ITRM:NASDAQ) Investor Relations Material

Overview

Dublin-based pharmaceutical company Iterum Therapeutics plc is making strides in the field of anti-infectives. The clinical-stage firm operates in Ireland, Bermuda, and the US, with a particular focus on developing and marketing anti-infectives. Its latest project, sulopenem, is a fresh anti-infective compound offered in both oral and IV formulations. Currently in Phase III clinical trials, sulopenem is being developed for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was established in 2015, and is now notching up significant progress in its anti-infectives work.

Frequently Asked Questions

What is Iterum Therapeutics plc's ticker?

Iterum Therapeutics plc's ticker is ITRM

What exchange is Iterum Therapeutics plc traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Iterum Therapeutics plc's headquarters?

They are based in Dublin, Ireland

How many employees does Iterum Therapeutics plc have?

There are 11-50 employees working at Iterum Therapeutics plc

What is Iterum Therapeutics plc's website?

It is https://www.iterumtx.com/

What type of sector is Iterum Therapeutics plc?

Iterum Therapeutics plc is in the Healthcare sector

What type of industry is Iterum Therapeutics plc?

Iterum Therapeutics plc is in the Biotechnology industry

Who are Iterum Therapeutics plc's peers and competitors?

The following five companies are Iterum Therapeutics plc's industry peers:

- Oyster Point Pharma Inc

- Revance Therapeutics

- Catalyst Biosciences, Inc.

- Proteomics International

- Cabaletta Bio, Inc.